Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 9:33 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 517 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Sepsis Clear all

Conditions: Jaundice and Sepsis in Neonates
Interventions: ceftriaxone; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 3 Days to 7 Days
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Severe Sepsis, Septic Shock, Microcirculation
Interventions: Sidestream Dark Field (SDF), Near Infrared Spectroscopy (NIRS); Device
Lead sponsor: Mercy Research; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Sepsis, Altered Mental Status, Sepsis-Associated Delirium, Sepsis Associated Encephalopathy, Delirium, Sepsis Associated
Interventions: Blood draws; Procedure
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Sepsis
Interventions: Blood samples collected; Procedure
Lead sponsor: Abbott RDx Cardiometabolic; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 24
States / cities: Los Angeles, California • Sylmar, California • Denver, Colorado + 16 more

Conditions: Sepsis, Infection
Interventions: Up-front individualized dosing algorithm, Usual Care; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Septic Shock
Interventions: Bevacizumab, Placebo; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 3
States / cities: Boston, Massachusetts • Camden, New Jersey • Charlotte, North Carolina

Conditions: Sepsis, Septicemia, Respiratory Failure, Hemodynamic Instability, COVID-19, Cardiac Arrest, Clinical Deterioration
Interventions: eCARTv5 clinical deterioration monitoring, Standard of care control; Device · Other
Lead sponsor: AgileMD, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 30,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 3
States / cities: New Haven, Connecticut • Clearwater, Florida • Madison, Wisconsin

Conditions: Delirium, Impaired Cognition, Long Term Psychologic Disorders
Interventions: Haloperidol, Ziprasidone, Placebo; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 566 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 16
States / cities: Denver, Colorado • New Haven, Connecticut • Indianapolis, Indiana + 12 more

Conditions: Sepsis, Severe, Septic Shock
Interventions: Smoflipid; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 3
States / cities: Gainesville, Florida • Jacksonville, Florida

Conditions: Severe Sepsis, Septic Shock
Interventions: Not listed
Lead sponsor: Sirius Genomics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 4
States / cities: Atlanta, Georgia • Baltimore, Maryland • Boston, Massachusetts + 1 more

Conditions: Sepsis
Interventions: GFR by Iohexol, Urine Collection, Blood samples; Diagnostic Test
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: ARDS, Sepsis, Pneumonia
Interventions: Blood collection, Urine Collection, Nasal, oral, and rectal swabs, Stool collection, Heat Moisture Exchange Filter collection, Tracheal Aspirate sample collection, Non-bronchoscopic bronchoalveolar lavage (NBBAL), Surveys, Short physical performance battery, Hand grip strength, CNS Vital Signs, Muscle Ultrasound, Muscle Strength, Spirometry, Lung Diffusion Testing (DLCO), Chest CT Scan; Other · Procedure · Radiation
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 4,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 20
States / cities: Fresno, California • Palo Alto, California • San Francisco, California + 12 more

Conditions: Sepsis Severe, Septic Shock
Interventions: Sepsis Bundle; Other
Lead sponsor: Rhode Island Hospital; Other
Eligibility: 18 Years and older
Enrollment: 10,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Chronic Granulomatous Disease, Infection
Interventions: gp91 Grans; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 75 Years · Male only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Septic Shock
Interventions: Not listed
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Anemia of Prematurity, Necrotizing Enterocolitis
Interventions: Not listed
Lead sponsor: University of Utah; Other
Eligibility: Up to 12 Weeks
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 3
States / cities: Murray, Utah • Salt Lake City, Utah

Conditions: Hypovitaminosis D
Interventions: Cholecalciferol, Placebo; Dietary Supplement
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Septic Shock, Shock, Sepsis, Systemic Inflammatory Response Syndrome
Interventions: Angiotensin II and hydrocortisone sodium succinate; Drug
Lead sponsor: Kingman Regional Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Kingman, Arizona

Conditions: Sepsis
Interventions: Çontrol, Hydrocortisone; Other · Drug
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Sepsis
Interventions: rPAF-AH; Drug
Lead sponsor: ICOS Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 2,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 1
States / cities: Bothell, Washington

Conditions: Sepsis, Bacteremia, Fungemia
Interventions: MBI 226; Drug
Lead sponsor: BioWest Therapeutics Inc; Industry
Eligibility: 16 Years and older
Enrollment: 1,400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2003
U.S. locations: 1
States / cities: Lake Bluff, Illinois

Conditions: Acute Lung Injury, Acute Respiratory Distress Syndrome
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 6,600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2020
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Bacteremia
Interventions: No intervention; Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 1,354 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2013
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Sepsis
Interventions: Observation; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Rochester, Minnesota

Search by objective public record fields.

Ceftriaxone and Jaundice in Neonates

The Effect of Three Different Fluids(Albumin 5%, Normal Saline, Hydroxyethyl Starch 130 kD) on Microcirculation in Severe Sepsis/Septic Shock Patients

Sepsis Associated Encephalopathy (SAE) Biomarkers

Multi-marker INDex for the Risk Assessment of Sepsis in the Emergency departmenT (MINDSET)

BLOOM: Pragmatic Feasibility Trial

Pilot Study of Bevacizumab (Avastin) in Patients With Septic Shock

A Rapid Diagnostic of Risk in Hospitalized Patients Using Machine Learning

The Modifying the Impact of ICU-Associated Neurological Dysfunction-USA (MIND-USA) Study

LIPIDS-P Trial Phase I/II Trial

Pharmacogenomic Biomarker Study for Recombinant Human Activated Protein C Treatment in Severe Sepsis

Kidney Response to Sepsis Affects Angiogenic Balance and Likelihood of CCI and PICS

The APS Phenotyping Study

Assessment for Implementation Methods in Sepsis

NADPH Oxidase Correction in mRNA-transfected Granulocyte-enriched Cells in Chronic Granulomatous Disease (CGD)

Vasopressin Plasma Concentrations in Patients Receiving Exogenous Vasopressin Infusion for Septic Shock

Transfusion-related Inflammatory Cytokine and Neutrophil Extracellular Trap Quantification in Neonates

Cholecalciferol Supplementation for Sepsis in the ICU

Hemodynamic Response to Angiotensin-II When Used as the Second Vasopressor Agent for Septic Shock

Cortisol Control of Human Inflammatory Responses to Endotoxin

Safety and Efficacy of Recombinant Human Platelet-Activating Factor Acetylhydrolase for the Treatment of Severe Sepsis

Safety and Efficacy of MBI 226 for the Prevention of Central Venous Catheter-Related Bloodstream Infections

Timing and Intensity of the Exposures and Attributable Burden of Acute Lung Injury

Virulence Determinants in S Aureus Bacteremia

Dynamics of Organ Damage and Immune Exhaustion During Sepsis